Comments
Loading...

ORIC Pharmaceuticals Analyst Ratings

ORICNASDAQ
Logo brought to you by Benzinga Data
$5.67
0.11.80%
At close: -
$5.68
0.010000.18%
After Hours: May 2, 7:03 PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$27.00
Lowest Price Target1
$14.00
Consensus Price Target1
$20.10

ORIC Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ORIC | Benzinga

ORIC Pharmaceuticals Inc has a consensus price target of $20.1 based on the ratings of 12 analysts. The high is $27 issued by Baird on August 16, 2023. The low is $14 issued by Citigroup on May 7, 2024. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and HC Wainwright & Co. on February 26, 2025, February 26, 2025, and February 24, 2025, respectively. With an average price target of $21.33 between JP Morgan, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 275.59% upside for ORIC Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
8
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JP Morgan
HC Wainwright & Co.
Wells Fargo
Jones Trading
Wedbush

1calculated from analyst ratings

Analyst Ratings for ORIC Pharmaceuticals

Buy NowGet Alert
02/26/2025Buy Now—Guggenheim
Michael Schmidt57%
—ReiteratesBuy → BuyGet Alert
02/26/2025Buy Now287.32%JP Morgan
Anupam Rama59%
$21 → $22MaintainsOverweightGet Alert
02/26/2025Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
02/24/2025Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
02/21/2025Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
02/11/2025Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now—Guggenheim
Michael Schmidt57%
—MaintainsBuyGet Alert
02/06/2025Buy Now269.72%JP Morgan
Anupam Rama59%
$19 → $21MaintainsOverweightGet Alert
01/14/2025Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—ReiteratesOverweight → OverweightGet Alert
01/13/2025Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
11/04/2024Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now252.11%Wells Fargo— → $20Initiates → OverweightGet Alert
10/31/2024Buy Now199.3%Jones Trading
Soumit Roy32%
→ $17Initiates → BuyGet Alert
09/23/2024Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—Reiterates → OverweightGet Alert
09/18/2024Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
09/10/2024Buy Now252.11%Wedbush
David Nierengarten60%
$20 → $20ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—Reiterates → OverweightGet Alert
09/06/2024Buy Now252.11%Stifel
Bradley Canino40%
→ $20Initiates → BuyGet Alert
08/14/2024Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
08/13/2024Buy Now252.11%Wedbush
David Nierengarten60%
$20 → $20ReiteratesOutperform → OutperformGet Alert
08/13/2024Buy Now164.08%Oppenheimer
Matthew Biegler37%
$17 → $15MaintainsOutperformGet Alert
07/17/2024Buy Now252.11%Wedbush
David Nierengarten60%
$20 → $20ReiteratesOutperform → OutperformGet Alert
07/17/2024Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$21 → $21ReiteratesBuy → BuyGet Alert
07/10/2024Buy Now199.3%Oppenheimer
Matthew Biegler37%
$17 → $17MaintainsOutperformGet Alert
06/20/2024Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—Reiterates → OverweightGet Alert
05/28/2024Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—Reiterates → OverweightGet Alert
05/07/2024Buy Now146.48%Citigroup
Yigal Nochomovitz56%
$15 → $14MaintainsBuyGet Alert
03/27/2024Buy Now216.9%JP Morgan
Anupam Rama59%
$19 → $18MaintainsOverweightGet Alert
03/21/2024Buy Now269.72%HC Wainwright & Co.
Robert Burns43%
$15 → $21MaintainsBuyGet Alert
03/12/2024Buy Now252.11%Wedbush
David Nierengarten60%
$20 → $20ReiteratesOutperform → OutperformGet Alert
03/12/2024Buy Now199.3%Oppenheimer
Matthew Biegler37%
$14 → $17MaintainsOutperformGet Alert
03/12/2024Buy Now340.14%Baird
Colleen Kusy35%
$27 → $25ReiteratesOutperform → OutperformGet Alert
03/01/2024Buy Now252.11%Wedbush
David Nierengarten60%
$12 → $20MaintainsOutperformGet Alert
02/23/2024Buy Now—Cantor Fitzgerald
Prakhar Agrawal40%
—Initiates → OverweightGet Alert
12/13/2023Buy Now164.08%HC Wainwright & Co.
Robert Burns43%
$16 → $15MaintainsBuyGet Alert
10/26/2023Buy Now181.69%HC Wainwright & Co.
Robert Burns43%
$13 → $16MaintainsBuyGet Alert
10/23/2023Buy Now146.48%Wedbush
David Nierengarten60%
→ $14ReiteratesOutperform → OutperformGet Alert
09/22/2023Buy Now146.48%Wedbush
David Nierengarten60%
→ $14Initiates → OutperformGet Alert
08/16/2023Buy Now375.35%Baird
Michael Ulz63%
$15 → $27MaintainsOutperformGet Alert
08/15/2023Buy Now128.87%HC Wainwright & Co.
Robert Burns43%
$14 → $13MaintainsBuyGet Alert
06/08/2023Buy Now146.48%HC Wainwright & Co.
Robert Burns43%
→ $14ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now146.48%HC Wainwright & Co.
Robert Burns43%
$16 → $14MaintainsBuyGet Alert
04/05/2023Buy Now40.85%Citigroup
Yigal Nochomovitz56%
$9 → $8MaintainsBuyGet Alert
03/23/2023Buy Now181.69%HC Wainwright & Co.
Robert Burns43%
→ $16UpgradeNeutral → BuyGet Alert
03/21/2023Buy Now164.08%JP Morgan
Anupam Rama59%
$16 → $15MaintainsOverweightGet Alert
03/21/2023Buy Now164.08%Guggenheim
Michael Schmidt57%
→ $15DowngradeBuy → NeutralGet Alert
03/16/2023Buy Now146.48%Oppenheimer
Matthew Biegler37%
→ $14UpgradePerform → OutperformGet Alert
05/20/2022Buy Now58.45%Citigroup
Yigal Nochomovitz56%
$10 → $9MaintainsBuyGet Alert

FAQ

Q

What is the target price for ORIC Pharmaceuticals (ORIC) stock?

A

The latest price target for ORIC Pharmaceuticals (NASDAQ:ORIC) was reported by Guggenheim on February 26, 2025. The analyst firm set a price target for $0.00 expecting ORIC to fall to within 12 months (a possible -100.00% downside). 27 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ORIC Pharmaceuticals (ORIC)?

A

The latest analyst rating for ORIC Pharmaceuticals (NASDAQ:ORIC) was provided by Guggenheim, and ORIC Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for ORIC Pharmaceuticals (ORIC)?

A

The last upgrade for ORIC Pharmaceuticals Inc happened on March 23, 2023 when HC Wainwright & Co. raised their price target to $16. HC Wainwright & Co. previously had a neutral for ORIC Pharmaceuticals Inc.

Q

When was the last downgrade for ORIC Pharmaceuticals (ORIC)?

A

The last downgrade for ORIC Pharmaceuticals Inc happened on March 21, 2023 when Guggenheim changed their price target from N/A to $15 for ORIC Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for ORIC Pharmaceuticals (ORIC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ORIC Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ORIC Pharmaceuticals was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.

Q

Is the Analyst Rating ORIC Pharmaceuticals (ORIC) correct?

A

While ratings are subjective and will change, the latest ORIC Pharmaceuticals (ORIC) rating was a reiterated with a price target of $0.00 to $0.00. The current price ORIC Pharmaceuticals (ORIC) is trading at is $5.68, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch